Drug Profile
Research programme: kinase inhibitors - Gilead Sciences
Alternative Names: ASK1i; TANK Binding Kinase 1 and and I-Kappa B Kinase Epsilon inhibitor - Gilead Sciences; TBK1/IKBKE inhibitor - Gilead sciencesLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics; Antirheumatics; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors; MAP kinase kinase kinase inhibitors; TBK1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Rheumatoid arthritis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 01 May 2017 Pharmacodynamics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AARC-2017)